Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 265

1.

Chikungunya and O'nyong-nyong Viruses in Uganda: Implications for Diagnostics.

Clements TL, Rossi CA, Irish AK, Kibuuka H, Eller LA, Robb ML, Kataaha P, Michael NL, Hensley LE, Schoepp RJ.

Open Forum Infect Dis. 2019 Jan 3;6(3):ofz001. doi: 10.1093/ofid/ofz001. eCollection 2019 Mar.

PMID:
31660384
2.

Genetic Clustering Analysis for HIV Infection among Men Who Have Sex with Men in Nigeria: implications for intervention.

Li Y, Liu H, Ramadhani HO, Ndembi N, Crowell TA, Kijak G, Robb ML, Ake JA, Kokogho A, Nowak RG, Gaydos C, Baral SD, Volz E, Tovanabutra S, Charurat M; TRUST/RV368 Study Group.

AIDS. 2019 Oct 11. doi: 10.1097/QAD.0000000000002409. [Epub ahead of print]

PMID:
31634185
3.

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial.

Pantaleo G, Janes H, Karuna S, Grant S, Ouedraogo GL, Allen M, Tomaras GD, Frahm N, Montefiori DC, Ferrari G, Ding S, Lee C, Robb ML, Esteban M, Wagner R, Bart PA, Rettby N, McElrath MJ, Gilbert PB, Kublin JG, Corey L; NIAID HIV Vaccine Trials Network.

Lancet HIV. 2019 Nov;6(11):e737-e749. doi: 10.1016/S2352-3018(19)30262-0. Epub 2019 Oct 7.

4.

Viral Blips after Treatment Initiation during Acute HIV Infection.

Crowell TA, Pinyakorn S, Sacdalan C, Kroon E, Colby DJ, Puttamaswin S, Ubolyam S, Trichavaroj R, Butterworth O, Turk E, McCullough C, Chomont N, de Souza M, Robb ML, Phanuphak N, Ananworanich J; RV254/SEARCH010 Study Group.

Clin Infect Dis. 2019 Sep 24. pii: ciz936. doi: 10.1093/cid/ciz936. [Epub ahead of print]

PMID:
31550044
5.

Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa.

Gray GE, Huang Y, Grunenberg N, Laher F, Roux S, Andersen-Nissen E, De Rosa SC, Flach B, Randhawa AK, Jensen R, Swann EM, Bekker LG, Innes C, Lazarus E, Morris L, Mkhize NN, Ferrari G, Montefiori DC, Shen X, Sawant S, Yates N, Hural J, Isaacs A, Phogat S, DiazGranados CA, Lee C, Sinangil F, Michael NL, Robb ML, Kublin JG, Gilbert PB, McElrath MJ, Tomaras GD, Corey L.

Sci Transl Med. 2019 Sep 18;11(510). pii: eaax1880. doi: 10.1126/scitranslmed.aax1880.

PMID:
31534016
6.

HIV prevalence and risk behavior among male and female adults screened for enrolment into a vaccine preparedness study in Maputo, Mozambique.

Macicame I, Bhatt N, Matavele Chissumba R, Eller LA, Viegas E, Araújo K, Nwoga C, Li Q, Milazzo M, Hills NK, Lindan C, Michael NL, Robb ML, Jani I, Polyak CS.

PLoS One. 2019 Sep 17;14(9):e0221682. doi: 10.1371/journal.pone.0221682. eCollection 2019.

7.

Terminal Effector CD8 T Cells Defined by an IKZF2+IL-7R- Transcriptional Signature Express FcγRIIIA, Expand in HIV Infection, and Mediate Potent HIV-Specific Antibody-Dependent Cellular Cytotoxicity.

Naluyima P, Lal KG, Costanzo MC, Kijak GH, Gonzalez VD, Blom K, Eller LA, Creegan M, Hong T, Kim D, Quinn TC, Björkström NK, Ljunggren HG, Serwadda D, Katabira ET, Sewankambo NK, Gray RH, Baeten JM, Michael NL, Wabwire-Mangen F, Robb ML, Bolton DL, Sandberg JK, Eller MA.

J Immunol. 2019 Oct 15;203(8):2210-2221. doi: 10.4049/jimmunol.1900422. Epub 2019 Sep 13.

8.

A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials.

Ehrenberg PK, Shangguan S, Issac B, Alter G, Geretz A, Izumi T, Bryant C, Eller MA, Wegmann F, Apps R, Creegan M, Bolton DL, Sekaly RP, Robb ML, Gramzinski RA, Pau MG, Schuitemaker H, Barouch DH, Michael NL, Thomas R.

Sci Transl Med. 2019 Aug 28;11(507). pii: eaaw4236. doi: 10.1126/scitranslmed.aaw4236.

PMID:
31462510
9.

Recipient Comorbidity and Survival Outcomes after Kidney Transplantation: a UK-wide Prospective Cohort Study.

Wu DA, Robb ML, Forsythe JLR, Bradley C, Cairns J, Draper H, Dudley C, Johnson RJ, Metcalfe W, Ravanan R, Roderick P, Tomson CRV, Watson CJE, Bradley JA, Oniscu GC.

Transplantation. 2019 Aug 19. doi: 10.1097/TP.0000000000002931. [Epub ahead of print]

PMID:
31449188
10.

Deep Sequencing Reveals Central Nervous System Compartmentalization in Multiple Transmitted/Founder Virus Acute HIV-1 Infection.

Tovanabutra S, Sirijatuphat R, Pham PT, Bonar L, Harbolick EA, Bose M, Song H, Chang D, Oropeza C, O'Sullivan AM, Balinang J, Kroon E, Colby DJ, Sacdalan C, Hellmuth J, Chan P, Prueksakaew P, Pinyakorn S, Jagodzinski LL, Sutthichom D, Pattamaswin S, de Souza M, Gramzinski RA, Kim JH, Michael NL, Robb ML, Phanuphak N, Ananworanich J, Valcour V, Kijak GH, Sanders-Buell E, Spudich S; MHRP Viral Sequencing Core; RV254/SEARCH 010 Study Team.

Cells. 2019 Aug 15;8(8). pii: E902. doi: 10.3390/cells8080902.

11.

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.

Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, Reuschel EL, Robb ML, Racine T, Oh MD, Lamarre C, Zaidi FI, Boyer J, Kudchodkar SB, Jeong M, Darden JM, Park YK, Scott PT, Remigio C, Parikh AP, Wise MC, Patel A, Duperret EK, Kim KY, Choi H, White S, Bagarazzi M, May JM, Kane D, Lee H, Kobinger G, Michael NL, Weiner DB, Thomas SJ, Maslow JN.

Lancet Infect Dis. 2019 Sep;19(9):1013-1022. doi: 10.1016/S1473-3099(19)30266-X. Epub 2019 Jul 24.

PMID:
31351922
12.

Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV.

Niu Q, Liu Z, Alamer E, Fan X, Chen H, Endsley J, Gelman BB, Tian B, Kim JH, Michael NL, Robb ML, Ananworanich J, Zhou J, Hu H.

J Clin Invest. 2019 Jul 22;129(8):3361-3373. doi: 10.1172/JCI120633. eCollection 2019 Jul 22.

13.

Switch to dolutegravir is well tolerated in Thais with HIV infection.

Goh OQ, Colby DJ, Pinyakorn S, Sacdalan C, Kroon E, Chan P, Chomchey N, Kanaprach R, Prueksakaew P, Suttichom D, Trichavaroj R, Spudich S, Robb ML, Phanuphak P, Phanuphak N, Ananworanich J; RV254/SEARCH 010 Study Group.

J Int AIDS Soc. 2019 Jul;22(7):e25324. doi: 10.1002/jia2.25324.

14.

Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-infection Estimation towards Enhanced Vaccine Efficacy Assessment.

Rossenkhan R, Rolland M, Labuschagne JPL, Ferreira RC, Magaret CA, Carpp LN, Matsen Iv FA, Huang Y, Rudnicki EE, Zhang Y, Ndabambi N, Logan M, Holzman T, Abrahams MR, Anthony C, Tovanabutra S, Warth C, Botha G, Matten D, Nitayaphan S, Kibuuka H, Sawe FK, Chopera D, Eller LA, Travers S, Robb ML, Williamson C, Gilbert PB, Edlefsen PT.

Viruses. 2019 Jul 3;11(7). pii: E607. doi: 10.3390/v11070607.

15.

Effect of HIV infection and antiretroviral therapy on immune cellular functions.

Korencak M, Byrne M, Richter E, Schultz BT, Juszczak P, Ake JA, Ganesan A, Okulicz JF, Robb ML, de Los Reyes B, Winning S, Fandrey J, Burgess TH, Esser S, Michael NL, Agan BK, Streeck H.

JCI Insight. 2019 Jun 20;4(12). pii: 126675. doi: 10.1172/jci.insight.126675. eCollection 2019 Jun 20.

16.

Decreased Seroreactivity in Individuals Initiating Antiretroviral Therapy during Acute HIV Infection.

Manak MM, Jagodzinski LL, Shutt A, Malia JA, Leos M, Ouellette J, Akapirat S, Colby DL, Phanuphak N, Eller LA, Robb ML, de Souza M, Ananworanich J, Peel SA; RV254/SEARCH010 and the RV217 Study Teams.

J Clin Microbiol. 2019 Sep 24;57(10). pii: e00757-19. doi: 10.1128/JCM.00757-19. Print 2019 Oct.

PMID:
31217270
17.

Correction: Trinh, H.V., et al. Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort. Cells 2019, 8, 365.

Trinh HV, Gohain N, Pham PT, Hamlin C, Song H, Sanders-Buell E, Bose M, Eller LA, Jain S, Uritskiy G, Rao VB, Tovanabutra S, Michael NL, Robb ML, Joyce MG, Rao M.

Cells. 2019 Jun 6;8(6). pii: E554. doi: 10.3390/cells8060554.

18.

The breadth of HIV-1 neutralizing antibodies depends on the conservation of key sites in their epitopes.

Bai H, Li Y, Michael NL, Robb ML, Rolland M.

PLoS Comput Biol. 2019 Jun 6;15(6):e1007056. doi: 10.1371/journal.pcbi.1007056. eCollection 2019 Jun.

19.

HIV-1 genetic diversity and demographic characteristics in Bulgaria.

Billings E, Heipertz RA, Varleva T, Sanders-Buell E, O'Sullivan AM, Bose M, Howell S, Kijak GH, Taskov H, Elenkov I, Nenova M, Popivanova N, Valenzuela AB, Myles O, Bautista CT, Robb ML, Michael NL, Kim JH, Scott PT, Tovanabutra S, Ake JA.

PLoS One. 2019 May 28;14(5):e0217063. doi: 10.1371/journal.pone.0217063. eCollection 2019.

20.

New Subtype B Containing HIV-1 Circulating Recombinant of sub-Saharan Africa Origin in Nigerian Men Who Have Sex With Men.

Billings E, Kijak GH, Sanders-Buell E, Ndembi N, OʼSullivan AM, Adebajo S, Kokogho A, Milazzo M, Lombardi K, Baral S, Nowak R, Ramadhani H, Gramzinski R, Robb ML, Michael NL, Charurat ME, Ake J, Crowell TA, Tovanabutra S; MHRP Viral Sequencing Core and the TRUST/RV368 Study Group.

J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):578-584. doi: 10.1097/QAI.0000000000002076.

PMID:
31107298
21.

Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and Sequence.

Nadai Y, Held K, Joseph S, Ahmed MIM, Hoffmann VS, Peterhoff D, Missanga M, Bauer A, Joachim A, Reimer U, Zerweck J, McCormack S, Cope AV, Tatoud R, Shattock RJ, Robb ML, Sandstroem EG, Hoelscher M, Maboko L, Bakari M, Kroidl A, Wagner R, Weber J, Pollakis G, Geldmacher C.

Front Immunol. 2019 Apr 24;10:717. doi: 10.3389/fimmu.2019.00717. eCollection 2019.

22.

Harnessing circulating microRNAs for early HIV diagnosis.

Vasan S, Robb ML.

EBioMedicine. 2019 Jun;44:18-19. doi: 10.1016/j.ebiom.2019.05.017. Epub 2019 May 13. No abstract available.

23.

Expansion of Stem Cell-Like CD4+ Memory T Cells during Acute HIV-1 Infection Is Linked to Rapid Disease Progression.

Pušnik J, Eller MA, Tassaneetrithep B, Schultz BT, Eller LA, Nitayaphan S, Kosgei J, Maganga L, Kibuuka H, Alter G, Michael NL, Robb ML, Streeck H.

J Virol. 2019 Jun 28;93(14). pii: e00377-19. doi: 10.1128/JVI.00377-19. Print 2019 Jul 15.

PMID:
31043532
24.

Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort.

Trinh HV, Gohain N, Pham PT, Hamlin C, Song H, Sanders-Buell E, Bose M, Eller LA, Jain S, Uritskiy G, Rao VB, Tovanabutra S, Michael NL, Robb ML, Joyce MG, Rao M.

Cells. 2019 Apr 19;8(4). pii: E365. doi: 10.3390/cells8040365. Erratum in: Cells. 2019 Jun 06;8(6):. Jain, Swati [added]; Uritskiy, Gherman [added]; Rao, Venigalla B [added].

25.

Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.

Crowell TA, Colby DJ, Pinyakorn S, Sacdalan C, Pagliuzza A, Intasan J, Benjapornpong K, Tangnaree K, Chomchey N, Kroon E, de Souza MS, Tovanabutra S, Rolland M, Eller MA, Paquin-Proulx D, Bolton DL, Tokarev A, Thomas R, Takata H, Trautmann L, Krebs SJ, Modjarrad K, McDermott AB, Bailer RT, Doria-Rose N, Patel B, Gorelick RJ, Fullmer BA, Schuetz A, Grandin PV, O'Connell RJ, Ledgerwood JE, Graham BS, Tressler R, Mascola JR, Chomont N, Michael NL, Robb ML, Phanuphak N, Ananworanich J; RV397 Study Group.

Lancet HIV. 2019 May;6(5):e297-e306. doi: 10.1016/S2352-3018(19)30053-0. Epub 2019 Apr 15.

PMID:
31000477
26.

Next-generation sequencing of HIV-1 single genome amplicons.

Kijak GH, Sanders-Buell E, Pham P, Harbolick EA, Oropeza C, O'Sullivan AM, Bose M, Beckett CG, Milazzo M, Robb ML, Peel SA, Scott PT, Michael NL, Armstrong AW, Kim JH, Brett-Major DM, Tovanabutra S.

Biomol Detect Quantif. 2019 Mar 11;17:100080. doi: 10.1016/j.bdq.2019.01.002. eCollection 2019 Mar.

27.

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.

Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, Colby DJ, Dawson L, Dong KL, Dubé K, Eron J, Frater J, Gandhi RT, Geleziunas R, Goulder P, Hanna GJ, Jefferys R, Johnston R, Kuritzkes D, Li JZ, Likhitwonnawut U, van Lunzen J, Martinez-Picado J, Miller V, Montaner LJ, Nixon DF, Palm D, Pantaleo G, Peay H, Persaud D, Salzwedel J, Salzwedel K, Schacker T, Sheikh V, Søgaard OS, Spudich S, Stephenson K, Sugarman J, Taylor J, Tebas P, Tiemessen CT, Tressler R, Weiss CD, Zheng L, Robb ML, Michael NL, Mellors JW, Deeks SG, Walker BD.

Lancet HIV. 2019 Apr;6(4):e259-e268. doi: 10.1016/S2352-3018(19)30052-9. Epub 2019 Mar 15. Review.

PMID:
30885693
28.

Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual.

Krebs SJ, Kwon YD, Schramm CA, Law WH, Donofrio G, Zhou KH, Gift S, Dussupt V, Georgiev IS, Schätzle S, McDaniel JR, Lai YT, Sastry M, Zhang B, Jarosinski MC, Ransier A, Chenine AL, Asokan M, Bailer RT, Bose M, Cagigi A, Cale EM, Chuang GY, Darko S, Driscoll JI, Druz A, Gorman J, Laboune F, Louder MK, McKee K, Mendez L, Moody MA, O'Sullivan AM, Owen C, Peng D, Rawi R, Sanders-Buell E, Shen CH, Shiakolas AR, Stephens T, Tsybovsky Y, Tucker C, Verardi R, Wang K, Zhou J, Zhou T, Georgiou G, Alam SM, Haynes BF, Rolland M, Matyas GR, Polonis VR, McDermott AB, Douek DC, Shapiro L, Tovanabutra S, Michael NL, Mascola JR, Robb ML, Kwong PD, Doria-Rose NA.

Immunity. 2019 Mar 19;50(3):677-691.e13. doi: 10.1016/j.immuni.2019.02.008. Epub 2019 Mar 12.

PMID:
30876875
29.

A sequestered fusion peptide in the structure of an HIV-1 transmitted founder envelope trimer.

Ananthaswamy N, Fang Q, AlSalmi W, Jain S, Chen Z, Klose T, Sun Y, Liu Y, Mahalingam M, Chand S, Tovanabutra S, Robb ML, Rossmann MG, Rao VB.

Nat Commun. 2019 Feb 20;10(1):873. doi: 10.1038/s41467-019-08825-7.

30.

HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study.

Kiweewa F, Esber A, Musingye E, Reed D, Crowell TA, Cham F, Semwogerere M, Namagembe R, Nambuya A, Kafeero C, Tindikahwa A, Eller LA, Millard M, Gelderblom HC, Keshinro B, Adamu Y, Maswai J, Owuoth J, Sing'oei VC, Maganga L, Bahemana E, Khamadi S, Robb ML, Ake JA, Polyak CS, Kibuuka H.

PLoS One. 2019 Feb 5;14(2):e0211344. doi: 10.1371/journal.pone.0211344. eCollection 2019.

31.

Time to change the paradigm: limited condom and lubricant use among Nigerian men who have sex with men and transgender women despite availability and counseling.

Crowell TA, Baral SD, Schwartz S, Nowak RG, Kokogho A, Adebajo S, Keshinro B, Makanjuola O, Michael NL, Robb ML, Charurat ME, Ake JA; TRUST/RV368 Study Group.

Ann Epidemiol. 2019 Mar;31:11-19.e3. doi: 10.1016/j.annepidem.2018.12.004. Epub 2018 Dec 21.

PMID:
30642695
32.

Molecular epidemiology of a primarily MSM acute HIV-1 cohort in Bangkok, Thailand and connections within networks of transmission in Asia.

Chang D, Sanders-Buell E, Bose M, O'Sullivan AM, Pham P, Kroon E, Colby DJ, Sirijatuphat R, Billings E, Pinyakorn S, Chomchey N, Rutvisuttinunt W, Kijak G, de Souza M, Excler JL, Phanuphak P, Phanuphak N, O'Connell RJ, Kim JH, Robb ML, Michael NL, Ananworanich J, Tovanabutra S; RV254/SEARCH 010 Study Group.

J Int AIDS Soc. 2018 Nov;21(11):e25204. doi: 10.1002/jia2.25204.

33.

Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy.

Whitney JB, Lim SY, Osuna CE, Kublin JL, Chen E, Yoon G, Liu PT, Abbink P, Borducci EN, Hill A, Lewis MG, Geleziunas R, Robb ML, Michael NL, Barouch DH.

Nat Commun. 2018 Dec 21;9(1):5429. doi: 10.1038/s41467-018-07881-9.

34.

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.

Viegas EO, Kroidl A, Munseri PJ, Missanga M, Nilsson C, Tembe N, Bauer A, Joachim A, Joseph S, Mann P, Geldmacher C, Fleck S, Stöhr W, Scarlatti G, Aboud S, Bakari M, Maboko L, Hoelscher M, Wahren B, Robb ML, Weber J, McCormack S, Biberfeld G, Jani IV, Sandström E, Lyamuya E; TaMoVac study group.

PLoS One. 2018 Nov 29;13(11):e0206838. doi: 10.1371/journal.pone.0206838. eCollection 2018.

35.

Noninfectious Comorbidity in the African Cohort Study (AFRICOS).

Ake JA, Polyak CS, Crowell TA, Kiweewa F, Semwogerere M, Maganga L, Bahemana E, Maswai J, Langat R, Owuoth J, Otieno S, Keshinro B, Esber AL, Liu M, Eller LA, Ganesan K, Parikh AP, Hamm TE, Robb ML, Hickey PW, Valcour VG, Michael NL; AFRICOS Study Team.

Clin Infect Dis. 2018 Nov 26. doi: 10.1093/cid/ciy981. [Epub ahead of print]

PMID:
30476001
36.

Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.

Pissani F, Schulte B, Eller MA, Schultz BT, Ratto-Kim S, Marovich M, Thongcharoen P, Sriplienchan S, Rerks-Ngarm S, Pitisuttithum P, Esser S, Alter G, Robb ML, Kim JH, Michael NL, Streeck H.

J Virol. 2018 Nov 12;92(23). pii: e01143-18. doi: 10.1128/JVI.01143-18. Print 2018 Dec 1.

37.

Biomarkers of Inflammation Correlate With Clinical Scoring Indices in Human Immunodeficiency Virus-Infected Kenyans.

Letizia A, Eller MA, Polyak C, Eller LA, Creegan M, Dawson P, Bryant C, D K, Crowell TA, Lombardi K, Rono E, Robb ML, Michael NL, Maswai J, Ake JA.

J Infect Dis. 2019 Jan 7;219(2):284-294. doi: 10.1093/infdis/jiy509.

PMID:
30165548
38.

A flow cytometry based assay that simultaneously measures cytotoxicity and monocyte mediated antibody dependent effector activity.

Alrubayyi A, Schuetz A, Lal KG, Jongrakthaitae S, Paolino KM, Ake JA, Robb ML, de Souza MS, Michael NL, Paquin-Proulx D, Eller MA.

J Immunol Methods. 2018 Nov;462:74-82. doi: 10.1016/j.jim.2018.08.012. Epub 2018 Aug 24.

39.

Transmission dynamics among participants initiating antiretroviral therapy upon diagnosis of early acute HIV-1 infection in Thailand.

Kroon E, Pham PT, Sirivichayakul S, Trichavaroj R, Colby DJ, Pinyakorn S, Phanuphak N, Sanders-Buell E, van Griensven F, Kijak GH, Kim JH, Michael NL, Robb ML, Ananworanich J, De Souza MS, Tovanabutra S; RV254/SEARCH 010 Study Group.

AIDS. 2018 Oct 23;32(16):2373-2381. doi: 10.1097/QAD.0000000000001956.

PMID:
30096068
40.

Evolution of HIV-1 within untreated individuals and at the population scale in Uganda.

Raghwani J, Redd AD, Longosz AF, Wu CH, Serwadda D, Martens C, Kagaayi J, Sewankambo N, Porcella SF, Grabowski MK, Quinn TC, Eller MA, Eller LA, Wabwire-Mangen F, Robb ML, Fraser C, Lythgoe KA.

PLoS Pathog. 2018 Jul 27;14(7):e1007167. doi: 10.1371/journal.ppat.1007167. eCollection 2018 Jul.

41.

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).

Barouch DH, Tomaka FL, Wegmann F, Stieh DJ, Alter G, Robb ML, Michael NL, Peter L, Nkolola JP, Borducchi EN, Chandrashekar A, Jetton D, Stephenson KE, Li W, Korber B, Tomaras GD, Montefiori DC, Gray G, Frahm N, McElrath MJ, Baden L, Johnson J, Hutter J, Swann E, Karita E, Kibuuka H, Mpendo J, Garrett N, Mngadi K, Chinyenze K, Priddy F, Lazarus E, Laher F, Nitayapan S, Pitisuttithum P, Bart S, Campbell T, Feldman R, Lucksinger G, Borremans C, Callewaert K, Roten R, Sadoff J, Scheppler L, Weijtens M, Feddes-de Boer K, van Manen D, Vreugdenhil J, Zahn R, Lavreys L, Nijs S, Tolboom J, Hendriks J, Euler Z, Pau MG, Schuitemaker H.

Lancet. 2018 Jul 21;392(10143):232-243. doi: 10.1016/S0140-6736(18)31364-3. Epub 2018 Jul 6.

42.

Acquisition of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Infection in a Patient Taking Preexposure Prophylaxis.

Colby DJ, Kroon E, Sacdalan C, Gandhi M, Grant RM, Phanuphak P, Ananworanich J, Robb ML, Phanuphak N.

Clin Infect Dis. 2018 Aug 31;67(6):962-964. doi: 10.1093/cid/ciy321.

43.

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.

Bekker LG, Moodie Z, Grunenberg N, Laher F, Tomaras GD, Cohen KW, Allen M, Malahleha M, Mngadi K, Daniels B, Innes C, Bentley C, Frahm N, Morris DE, Morris L, Mkhize NN, Montefiori DC, Sarzotti-Kelsoe M, Grant S, Yu C, Mehra VL, Pensiero MN, Phogat S, DiazGranados CA, Barnett SW, Kanesa-Thasan N, Koutsoukos M, Michael NL, Robb ML, Kublin JG, Gilbert PB, Corey L, Gray GE, McElrath MJ; HVTN 100 Protocol Team.

Lancet HIV. 2018 Jul;5(7):e366-e378. doi: 10.1016/S2352-3018(18)30071-7. Epub 2018 Jun 18.

44.

Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection.

Colby DJ, Trautmann L, Pinyakorn S, Leyre L, Pagliuzza A, Kroon E, Rolland M, Takata H, Buranapraditkun S, Intasan J, Chomchey N, Muir R, Haddad EK, Tovanabutra S, Ubolyam S, Bolton DL, Fullmer BA, Gorelick RJ, Fox L, Crowell TA, Trichavaroj R, O'Connell R, Chomont N, Kim JH, Michael NL, Robb ML, Phanuphak N, Ananworanich J; RV411 study group.

Nat Med. 2018 Jul;24(7):923-926. doi: 10.1038/s41591-018-0026-6. Epub 2018 Jun 11.

45.

Distinct biomarker signatures in HIV acute infection associate with viral dynamics and reservoir size.

Teigler JE, Leyre L, Chomont N, Slike B, Jian N, Eller MA, Phanuphak N, Kroon E, Pinyakorn S, Eller LA, Robb ML, Ananworanich J, Michael NL, Streeck H, Krebs SJ; RV254/RV217 study groups.

JCI Insight. 2018 May 17;3(10). pii: 98420. doi: 10.1172/jci.insight.98420. eCollection 2018 May 17.

46.

Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying env from an RV144 Volunteer to Rhesus Macaques: Coreceptor Switch and Final Recovery of a Pathogenic Virus with Exclusive R5 Tropism.

Scinto HB, Gupta S, Thorat S, Mukhtar MM, Griffiths A, Delgado J, Plake E, Vyas HK, Strickland A, Byrareddy SN, Montefiori DC, LaBranche C, Pal R, Treece J, Orndorff S, Ferrari MG, Weiss D, Chenine AL, McLinden R, Michael N, Kim JH, Robb ML, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Ruprecht RM.

J Virol. 2018 Jun 29;92(14). pii: e02222-17. doi: 10.1128/JVI.02222-17. Print 2018 Jul 15.

47.

Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.

Akapirat S, Karnasuta C, Vasan S, Rerks-Ngarm S, Pitisuttithum P, Madnote S, Savadsuk H, Rittiroongrad S, Puangkaew J, Phogat S, Tartaglia J, Sinangil F, de Souza MS, Excler JL, Kim JH, Robb ML, Michael NL, Ngauy V, O'Connell RJ, Karasavvas N; RV305 Study Group.

PLoS One. 2018 Apr 27;13(4):e0196397. doi: 10.1371/journal.pone.0196397. eCollection 2018.

48.

Reply to Chen et al.

Colby DJ, Posuwan N, Kroon E, Phanuphak N, Ananworanich J, Robb ML, Phanuphak P, Poovorawan Y; SEARCH010/RV254 Study Team.

J Infect Dis. 2018 Jul 2;218(3):505-507. doi: 10.1093/infdis/jiy161. No abstract available.

PMID:
29688398
49.

First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.

Baden LR, Walsh SR, Seaman MS, Cohen YZ, Johnson JA, Licona JH, Filter RD, Kleinjan JA, Gothing JA, Jennings J, Peter L, Nkolola J, Abbink P, Borducchi EN, Kirilova M, Stephenson KE, Pegu P, Eller MA, Trinh HV, Rao M, Ake JA, Sarnecki M, Nijs S, Callewaert K, Schuitemaker H, Hendriks J, Pau MG, Tomaka F, Korber BT, Alter G, Dolin R, Earl PL, Moss B, Michael NL, Robb ML, Barouch DH; IPCAVD006/RV380/HIV-V-A002 Study Group.

J Infect Dis. 2018 Jul 13;218(4):633-644. doi: 10.1093/infdis/jiy212.

50.

Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells during health and HIV disease.

Buggert M, Nguyen S, McLane LM, Steblyanko M, Anikeeva N, Paquin-Proulx D, Del Rio Estrada PM, Ablanedo-Terrazas Y, Noyan K, Reuter MA, Demers K, Sandberg JK, Eller MA, Streeck H, Jansson M, Nowak P, Sönnerborg A, Canaday DH, Naji A, Wherry EJ, Robb ML, Deeks SG, Reyes-Teran G, Sykulev Y, Karlsson AC, Betts MR.

PLoS Pathog. 2018 Apr 13;14(4):e1006973. doi: 10.1371/journal.ppat.1006973. eCollection 2018 Apr.

Supplemental Content

Support Center